{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:02:47Z","timestamp":1784581367394,"version":"3.55.0"},"reference-count":44,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00163","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T04:10:45Z","timestamp":1490674245000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Perrine","family":"Dusser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Kon\u00e9-Paut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.4049\/jimmunol.1600388","article-title":"Inositol-triphosphate 3-kinase C mediates inflammasome activation and treatment response in kawasaki disease.","volume":"197","author":"Alphonse","year":"2016","journal-title":"J. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/ni.2919","article-title":"The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response.","volume":"15","author":"Baroja-Mazo","year":"2014","journal-title":"Nat. Immunol."},{"key":"B3","first-page":"1103","article-title":"Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial.","volume":"31","author":"Bresnihan","year":"2004","journal-title":"J. Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1086\/323155","article-title":"CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease.","volume":"184","author":"Brown","year":"2001","journal-title":"J. Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1161\/CIRCULATIONAHA.112.093930","article-title":"Of mice and children: lessons from a Kawasaki mouse model.","volume":"125","author":"Burns","year":"2012","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","article-title":"Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.","volume":"153","author":"Burns","year":"2008","journal-title":"J. Pediatr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(04)16814-1","article-title":"Kawasaki syndrome.","volume":"364","author":"Burns","year":"2004","journal-title":"Lancet Lond. Engl."},{"key":"B8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/art.39975","article-title":"Found in Translation: international initiatives pursuing interleukin-1 blockade for treatment of acute Kawasaki Disease.","volume":"69","author":"Burns","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpeds.2004.12.022","article-title":"Infliximab treatment for refractory Kawasaki syndrome.","volume":"146","author":"Burns","year":"2005","journal-title":"J. Pediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/344633a0","article-title":"Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.","volume":"344","author":"Carter","year":"1990","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody.","volume":"51","author":"Chakraborty","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/heartjnl-2012-302126","article-title":"Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.","volume":"99","author":"Chen","year":"2013","journal-title":"Heart"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1136\/annrheumdis-2012-201658","article-title":"A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation.","volume":"71","author":"Cohen","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/archdischild-2012-302841","article-title":"Management of Kawasaki disease.","volume":"99","author":"Eleftheriou","year":"2014","journal-title":"Arch. Dis. Child."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis.","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.humimm.2010.06.008","article-title":"Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.","volume":"71","author":"Fury","year":"2010","journal-title":"Hum. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.autrev.2009.12.004","article-title":"Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin.","volume":"9","author":"Galeotti","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.drudis.2016.08.004","article-title":"Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease.","volume":"21","author":"Galeotti","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"467","key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00467","article-title":"IL-1 inhibition in systemic juvenile idiopathic arthritis.","volume":"7","author":"Giancane","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2249.2011.04533.x","article-title":"Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.","volume":"167","author":"Goldbach-Mansky","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B23","first-page":"178","article-title":"[Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].","volume":"16","author":"Kawasaki","year":"1967","journal-title":"Arerugi"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1586\/1744666X.2015.1077702","article-title":"Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.","volume":"11","author":"Kon\u00e9-Paut","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1161\/CIRCULATIONAHA.111.072769","article-title":"Interleukin-1\u03b2 is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease.","volume":"125","author":"Lee","year":"2012","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jbspin.2013.09.004","article-title":"Coronary artery abnormalities in children with systemic-onset juvenile idiopathic arthritis.","volume":"81","author":"Lef\u00e8vre-Utile","year":"2014","journal-title":"Joint Bone Spine"},{"key":"B27","first-page":"S3","article-title":"Can we prevent long term cardiac damage in Kawasaki disease? Lessons from Lactobacillus casei cell wall-induced arteritis in mice.","volume":"11(Suppl. 9)","author":"Lehman","year":"1993","journal-title":"Clin. Exp. Rheumatol."},{"key":"B28","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/art.1780280609","article-title":"Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension.","volume":"28","author":"Lehman","year":"1985","journal-title":"Arthritis Rheum."},{"key":"B29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cell.2004.05.004","article-title":"Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases.","volume":"117","author":"Martinon","year":"2004","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00431-007-0642-5","article-title":"Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin.","volume":"167","author":"Miura","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2016.1159120","article-title":"Serum ferritin levels as a useful diagnostic marker for the distinction of systemic juvenile idiopathic arthritis and Kawasaki disease.","author":"Mizuta","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1542\/peds.2004-2182","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, american heart association.","volume":"114","author":"Newburger","year":"2004","journal-title":"Pediatrics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jjcc.2008.08.002","article-title":"The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.","volume":"53","author":"Ogata","year":"2009","journal-title":"J. Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.","volume":"201","author":"Pascual","year":"2005","journal-title":"J. Exp. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1161\/CIRCULATIONAHA.105.537530","article-title":"TLR2 and MyD88 contribute to Lactobacillus casei extract-induced focal coronary arteritis in a mouse model of Kawasaki disease.","volume":"112","author":"Rosenkranz","year":"2005","journal-title":"Circulation"},{"issue":"19","key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0228-7","article-title":"Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.","volume":"10","author":"Rossi-Semerano","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nrrheum.2016.166","article-title":"Interleukin-1 function and role in rheumatic disease.","volume":"12","author":"Schett","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.4049\/jimmunol.0901395","article-title":"Involvement of innate and adaptive immunity in a murine model of coronary arteritis mimicking Kawasaki disease.","volume":"183","author":"Schulte","year":"2009","journal-title":"J. Immunol."},{"issue":"26","key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-12-26","article-title":"High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report.","volume":"12","author":"Shafferman","year":"2014","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jpeds.2010.10.012","article-title":"Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.","volume":"158","author":"Son","year":"2011","journal-title":"J. Pediatr."},{"key":"B42","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1136\/annrheumdis-2011-201268","article-title":"Treatment of autoinflammatory diseases: results from the eurofever registry and a literature review.","volume":"72","author":"Ter Haar","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.semarthrit.2014.07.007","article-title":"Macrophage activation syndrome in Kawasaki disease: more common than we thought?","volume":"44","author":"Wang","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"B44","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1253\/circj.CJ-10-0542","article-title":"Cytokine genetic polymorphisms and susceptibility to Kawasaki disease in Taiwanese children.","volume":"74","author":"Weng","year":"2010","journal-title":"Circ. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T13:36:29Z","timestamp":1498397789000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,28]]},"references-count":44,"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00163","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,28]]}}}